Kathleen P. Richton
CIK: 0002145406
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ENGN
enGene Therapeutics Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Richton Kathleen P.
Richton Kathleen P. (SEC CIK 0002145406) files insider reports with the SEC as SVP, Finance and Treasurer of enGene Therapeutics Inc. (ENGN).
Signal8 holds 1 ownership filing by Richton Kathleen P., a Form 3, filed on Jul 22, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Richton Kathleen P.'s filings is in SAINT-LAURENT.
Other insiders filing for enGene Therapeutics Inc. (ENGN)
- Grossman William, Interim Chief Medical Officer
- Chinoporos Constantine, Interim Chief Business Officer
- Astley-Sparke Philip, Director
- BRUNK GERALD A, Director
- Glickman Richard M, Director
- HASTINGS PAUL J, Director